Uveal melanoma is an intraocular malignancy that, depending on its size and genetic make-up, may lead to metastases in up to 50% of cases. Currently, no therapy has been proven to improve survival. However, new therapies exploiting immune responses against metastases are being developed. The primary tumor is well characterized: tumors at high risk of developing metastases often contain macrophages and lymphocytes. However, these lymphocytes are often regulatory T cells that may suppress immune response. Currently, immune checkpoint inhibitors have shown marked efficacy in multiple cancers (eg, cutaneous melanoma) but do not yet improve survival in uveal melanoma patients. More knowledge needs to be acquired regarding the function of T cells in uveal melanoma. Other therapeutic options are related to the biochemical pathways. Targeting the RAF-MEK-ERK pathway with small molecule MEK inhibitors abrogates the growth of UM cells harboring GNAQ/GNA11 Q209 mutations, suggesting that these aberrant G-protein oncogenes mediate, at least in part, their effect through this hallmark proliferation pathway. Other pathways are also implicated, such as those involving c-Jun and YAP. Further studies may show how interference in the different pathways may affect survival.
U veal melanoma (UM) is an ocular malignancy that is most common in individuals between the ages of 60 and 65, 1 although younger ages have been reported in Asia (median age at diagnosis of 49 in Chinese patients 2 and 46 in Indian cases). 3 This malignancy arises from melanocytes residing in the iris, ciliary body, or choroid 4 and may lead to metastases, which occur in up to 50% of patients. 5 Metastases are often seen in the liver but may also develop in other organs, such as the skin or the lungs. 6 A wide range of clinical, histopathological, and genetic changes have been associated with prognosis. 7 Large tumors with an anterior location (ciliary body) carry a worse prognosis than more posteriorly located tumors, and the presence of epithelioid cells is also a sign of an unfavorable prognosis. Specific chromosome changes are associated with either a good or a bad prognosis: the presence of extra copies of chromosome 6p is associated with a good prognosis, whereas extra copies of 8q and loss of 1 chromosome 3 are associated with a bad prognosis. 8 Another way to differentiate between a tumor with a good and a bad prognosis is by studying the tumor's mRNA expression pattern. Several studies identified that prognostically bad UM have a different mRNA expression pattern than prognostically good tumors and that this pattern is related to the chromosome constitution of the tumor.
9-11 A prognostic test based on the differences in expression has been developed. 12 This test identifies class 1 tumors with a favorable prognosis and class 2 tumors with a poor clinical outcome. Class 2 cases have been subdivided into class 2A and class 2B, with the latter group showing earlier onset of metastases. 13 Recently, a similar subclustering has been made for class 1 tumors: class 1A (2% 5-year metastatic risk) and class 1B (21% 5-year metastatic risk).
14 Although we can predict quite well which patient is going to develop metastases within a few years, effective treatments of these metastases are currently lacking. The best option is, when possible, to directly treat liver metastases, for example, through surgery or isolated hepatic perfusion with chemotherapeutics.
15 Future treatment options can be immunological or through individualized chemotherapy. To be able to select effective therapies, we have to understand the immunological behavior of the tumor and the molecular pathways that can be targeted by personalized approaches. We will describe the behavior of the different types of UM.
POPULATION
Uveal melanoma occurs more frequently in the same type of person as cutaneous melanoma, 1 being much more common in whites than in blacks and Asians. 16 The age-adjusted incidence of UM is 6 per million per year in whites, 0.31 in blacks, and 0.38 in Asians.
17 Both tumors tend to develop more frequently in individuals with light skin who do not tan easily after sun exposure and have blond hair and a light iris color. 18 The genetic background for these reported risk factors is complex and involves more than 1 gene. Because variants in the melanocortin-1 receptor (MC1R) gene play an important role in the regulation of melanin levels and are linked to skin and hair color, this gene was studied in UM. However, no difference in distribution was seen between UM patients and controls.
19 Blue eyes carry a higher risk of developing UM.
18 Eye color is linked to single nucleotide polymorphisms (SNPs) in several genes including OCA2, HERC2, SLC24A4, and TYR, and 1 study showed that, based on SNPs of these genes, the When specific genetic markers for cutaneous melanoma were tested in 272 cases of UM, an association was found between the occurrence of UM and 3 SNP variants that are located in the region of HERC2/OCA2, which determines eye color. 21 The association between blue eye color and UM development may explain the unexpected distribution of UM, with a higher frequency in the northern part than in the southern part of Europe, as blueeyed people constitute a larger part of the population in the north (eg, Ireland, Poland) than the south (eg, Italy, Portugal). 22 The risk associated with light-pigmented eyes also explains the low incidence of UM in Asians, as the majority of Asians have darkly pigmented eyes. The total number of melanocytes in the irides of Asians has been shown to be lower than in whites; however, this is unlikely to be the reason for the lower incidence of UM, as the irides of blacks have been shown to have melanocyte numbers comparable to whites, but the incidence of UM in blacks is as low as in Asians.
23 Light-colored irides carry relatively more pheomelanin than eumelanin in their iris melanocytes, which may have pro-oxidant characteristics.
24 Eye color may also have prognostic significance: 2 studies have indicated that having blue or gray eyes increases the risk of dying from metastases of UM. 25, 26 Germline mutations in CDKN2A and CDK4 convey an increased risk of developing cutaneous melanoma.
1,27 Individuals with a mutation in CDKN2A have a 70% lifetime risk of cutaneous melanoma, a 15% risk of pancreatic cancer, and an increased risk of developing lung cancer. However, these genes are not specifically associated with familial UM.
28 Accordingly, in a study of 385 patients with UM, only 1 case with a germline mutation in CDKN2A was detected. 29 More recently, a germline mutation in another gene, BAP1, was found to be associated with the familial occurrence of UM and also with several other malignancies, such as mesothelioma, renal cell carcinoma, and cutaneous melanoma.
27,30-32 About 2-4% of UM patients probably carry this mutation, as do about 20% of individuals who have familial UM.
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Patients with a germline BAP1 mutation may have atypical intradermal tumors, known as MBAITs (melanocytic BAP1-mutated atypical intradermal tumors).
33

SUN EXPOSURE
An association between sun exposure and the development of UM has been suggested, but no increase in the incidence of UM has been observed in countries such as Australia, though an increase in cutaneous melanoma has been reported there. In contrast to cutaneous melanoma, The Cancer Genome Atlas (TCGA) project has found a low frequency of ultraviolet light signature mutations in UM (TCGA project, unpublished data, 2017) . However, the relationship with sun exposure may depend on the location in the eye: de Lange et al 34 reported that sunlight-induced types of mutations specifically occur in the posterior part of the eye, the macular area, whereas this type of mutation occurred less frequently in ciliary body/peripheral choroidal melanoma.
34 Ciliochoroidal tumors were associated with light-colored eyes, carrying especially pheomelanin.
MUTATIONS AND CHROMOSOME ABERRATIONS
Although cutaneous and uveal melanoma occur in the same type of person and share some biochemical pathways, their Asia-Pacific Journal of Ophthalmology • Volume 6, Number 2, March/April 2017 underlying mutations and immunological characteristics differ. These similarities and differences are important parameters to understand why these tumors develop and insight is essential to find appropriate therapies. Mutually exclusive mutations in genes within the G-protein signaling pathway are nearly universal in UM but are present in varying frequencies: GNAQ (~45%), GNA11 (~45%), CYSLTR2 (<5%), and PLCB4 (<5%).
34-38 This differentiates these tumors from cutaneous melanoma, in which mutations in the BRAF, NRAS, and KIT genes occur. 39 These mutations are also seen in conjunctival melanoma, which therefore resembles cutaneous melanoma more than UM. 40 We would assume that mutations in GNAQ or GNA11 drive melanocyte proliferation in the majority of UMs, with subsequent mutations occurring in other genes, allowing cancerous spreading.
In addition to the mutations in the G-protein signaling pathway that characterize UM, other mutations have been identified. Such somatic mutations occur in SF3B1, EIF1AX, and BAP1 and are also mutually exclusive. 41, 42 Two main types of UM can be recognized according to the copy number of chromosome 3: tumors either have 2 copies of chromosome 3 [ie, disomy 3 (D3)] or they carry only 1 copy of chromosome 3 [ie, monosomy 3 (M3)]. These 2 different types of melanoma are associated with specific secondary mutations: the majority of M3 cases harbor mutations in the BAP1 gene.
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This gene is located on chromosome 3, and the loss of 1 chromosome 3 with an accompanying mutation in the BAP1 gene of the other chromosome leads to loss of expression of BAP1, 30 which is associated with the development of metastases. 43 The BAP1 protein is involved in the epigenetic regulation of gene expression by deubiquitinating histone H2A. The loss of BAP1 in UM has been shown to result in the loss of the melanocytic phenotype of tumor cells. 44 Uveal melanoma can be further divided according to the distribution of other chromosomes, such as gain of 6p or 8q. Disomy 3 tumors may either carry EIF1AX or SF3B1 mutations, the latter of which is associated with extra copies of 8q. 45 The EIF1AX gene encodes a protein which is involved in the initiation of translation of mRNA, 46 whereas the SF3B1 gene encodes for a spliceosome component involved in early stages of splicing.
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A division between UM can also be made according to gene expression profile (GEP). After several centers had reported that UM may show 1 of 2 specific RNA expression patterns, Onken et al 12 showed that the expression of a specific set of 12 mRNAs can be used as a routine test for identifying prognostically bad tumors. 9, 10, 12, 48 Another prognostically relevant division among D3 tumors can be made on the basis of PRAME (preferentially expressed antigen in melanoma) gene expression. Although the majority of metastases are associated with loss of 1 chromosome 3 (GEP class 2), a minority of patients with a disomy 3 (GEP class 1) tumor develop metastases. Field et al 49 identified elevated expression of PRAME as a marker of metastases in disomy 3 (GEP class 1) tumors. PRAME expression was associated with the presence of an SF3B1 mutation; gain of 1q, 6p, 8q, and 9q; and loss of 6q and 11q.
Monosomy 3/BAP1 mutant tumors differ greatly from D3/ BAP1 wild-type tumors in many characteristics, including mRNA, miRNA, and lncRNA expression patterns and gene methylation patterns (TCGA project, unpublished data, 2017) . Monosomy 3/ BAP1 mutant tumors give rise to metastases and correspond with the GEP class 2 group based on their expression patterns.
11,42 The M3/BAP1 mutant tumors can be divided into 2 groups based on their immune gene expression patterns, with 1 group showing more infiltrating leukocytes than the other. 43 This difference does not translate into a difference in metastatic behavior but may be relevant for immunotherapeutic approaches.
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PRESENCE OF IMMUNE INFILTRATE IN RELATION TO CLASS AND CHROMOSOME STATUS
The presence of an inflammatory phenotype is related to the presence of loss of 1 chromosome 3/loss of BAP1 expression. 43, 50 This inflammatory phenotype is made up of lymphocytes and macrophages, which are mainly of the tumor-enhancing M2 type (see below), and is characterized by a high expression of human leukocyte antigen (HLA) class I molecules on the tumor cells.
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Most of the infiltrating T cells are CD8+ T cells, which often lack IL-2R (CD25), limiting their capacity to be stimulated by IL-2. Regulatory T cells are often found among the CD4+ cells. They express Foxp3, function as suppressors of immune responses, and their presence in UM is linked to a bad prognosis. 53, 54 It has been hard to grow tumor-infiltrating T cells from UM and to assess their function. 55 One of the reasons is that the presence of UM cells in the same culture of the T cells inhibits the outgrowth of these T cells: UM cells have an inhibiting instead of a stimulating effect on their own autologous T cells. Immunotherapy is currently based on the principle that one should de-block the body's own immune responses against neoantigens. This can be achieved by using monoclonal antibodies directed against immune inhibitors, such as CTLA4, PD-1, and PD-L1. Regrettably, such therapies have not yet shown much success in UM, 56,57 and one wonders whether this is due to the same reason that autologous T cells have great difficulty proliferating in the presence of autologous UM cells (G. Gezgin, personal observation).
We do know that UM cells are vulnerable to T cell-mediated lysis. 55 We recently tested the sensitivity of a series of UM cell lines to lysis by PRAME-specific T cells and observed excellent lysis.
58 Furthermore, it is well known that UM cell lines can be lysed by natural killer (NK) cells, which are active in the blood and in the liver. 59, 60 The susceptibility of UM cell lines to NK cell-mediated lysis has been shown to be dependent on the level of HLA expression: tumors with a high HLA class I expression resist NK cell-mediated lysis, as was shown in murine experiments. Blocking NK cell function led to an increase in metastasis formation in a UM model in mice. 59, 61 As liver metastases are the main type of deadly metastases, it is not surprising that especially tumors with a high HLA class I expression give rise to metastases. 51 This phenomenon should make the metastases good targets for T cell-mediated immunotherapies, as T cells need a high HLA expression to recognize and kill a tumor cell.
Whereas loss of 1 chromosome 3/loss of BAP1 expression is associated with the presence of local inflammation, in addition, a subpopulation of the D3/BAP1-positive tumors are infiltrated by macrophages. We recently noticed an association between extra copies of 8q and an increased macrophage infiltration in D3 tumors. 62 One may consider the option that mutations in GNAQ and GNA11 already trigger the influx of macrophages at an early stage. Mutations in these 2 genes lead to YAP dephosphorylation and expression of the YAP protein. 63 Expression of YAP has been associated with production of different chemokines and cytokines in other malignancies and may well be responsible for the influx of macrophages at an early phase of development of uveal nevi and melanoma. It may even be that normal melanocytes can provide a trigger to attract macrophages: Jehs et al 63 showed that the supernatant of most cultures of unstimulated human choroidal melanocytes was able to stimulate monocyte migration.
64 This is a characteristic that is also seen in UM tumor cells, as in vitro studies from our lab showed that cultured UM cells are able to produce a range of cytokines that attract macrophages and that exposure of UM cells to hypoxia leads to further stimulation of the production of such cytokines. 65, 66 The majority of UM contain macrophages, and these tumorinfiltrating macrophages may have many different functions. Two main types of macrophages have been identified, known as M1 and M2 macrophages. The classically activated M1 macrophage can stimulate immune responses, plays a role in clearing bacterial infections, and has an antiangiogenic function. The M2 macrophage, on the other hand, is proangiogenic and anti-inflammatory, and this is the main type of macrophage observed in UM. 52, 67 In UM, a high number of macrophages is associated with an increased vessel density. 52, 68 As metastasis formation is mainly hematogenic, vessels are important for tumor spread; Ly et al 69 observed that this increased vessel density is indeed associated with an increase in death due to metastases.
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IMMUNE ESCAPE MECHANISMS
The presence of specific T cells and a high expression of HLA class I antigens on primary and metastatic UM cells should lead to effective T cell-mediated immune responses and make UM a good target for immunotherapies. Current approaches in cutaneous melanoma include the use of monoclonal antibodies directed against CTLA4, PD1, and PD-L1.
70,71 PD-L1 is a cell membrane molecule that can induce apoptosis in T cells that carry its receptor, PD1, thus blocking T cell-mediated tumor cell lysis. A blocker of PD-L1 (eg, atezolizumab) and blockers of PD1 (pembrolizumab and nivolumab) are being used quite successfully in different malignancies.
72-74 Both ligands are expressed in UM. 75 However, a Dutch trial in 22 patients with the anti-CTLA4 monoclonal antibody ipilimumab did not show much effect, with a 1-year survival rate of 27%.
76 A 10-patient trial with pembrolizumab for the treatment of metastatic UM resulted in 1 complete response, 2 partial responses, and 1 patient with stable disease.
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The lack of effect may be due to the effect of local inflammation: expression of PD-L1 becomes upregulated in the presence of interferon-gamma, and exposure of UM cells to interferon-gamma makes them resistant to T cell-mediated lysis. 78 We noticed that UM with an inflammatory phenotype express a wide array of interferon-gamma stimulated molecules (including a high expression of HLA-A, HLA-B, and b2-microglobulin), and these are especially the tumors that give rise to metastases (the M3 tumors). 79 Placing UM tissues as a xenograft in an immunologically deficient mouse led to loss of infiltrating immune cells and a downregulation of interferon-stimulated molecules.
79 A study on expression of HLA-related genes in primary UM showed that tumors with increased levels of HLA class I and II antigens showed an increase in the transcriptional regulators IRF1, IRF8, CIITA, and NLRC5. We already know that EZH2 (enhancer of zeste homologue 2, a polycomb repressive complex 2 subunit) helps to regulate CIITA expression, but we do not yet know how M3/loss of BAP1 interacts with this pathway, although there clearly is an interaction, as loss of BAP1 expression is associated with the upregulation of all of these transcriptional regulators.
Another immune escape mechanism that tumors display is the production of cytokines that inhibit T cells. One such molecule is IDO (indoleamine 2,3-dioxygenase), an enzyme that can help to degrade tryptophan, an essential molecule for T cell proliferation.
80 IDO also suppresses the cytolytic activity of NK cells. Uveal melanoma cells are known to produce IDO when stimulated by interferon, making it an effective immune escape strategy when under attack by cytotoxic T cells.
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MOLECULAR PATHWAYS
Since the first observations that up to approximately 90% of UM tumors harbor mutually exclusive mutations in GNAQ or GNA11, 35, 36 there has been an effort to better understand the molecular effectors of these constitutively active aberrant G-protein oncogenes. Inferring from the substantial prior literature examining the downstream effectors of activated GNAQ/GNA11, early studies focused on the well-described PLCβ-PKC and MEK-ERK pathways. The initial studies by Van Raamsdonk et al 35, 36 showed that introduction of either the GNAQ or GNA11 Q209L mutation into immortalized mouse melanocytes heightened phospho-ERK levels relative to wild-type cells and resulted in the development of pigmented tumors in this mouse model system. Conversely, knockdown of GNAQ/11 resulted in diminished phopho-ERK level.
35,36 These studies were followed by multiple investigations which showed that targeting the RAF-MEK-ERK pathway with small molecule MEK inhibitors could abrogate the growth of UM cells harboring GNAQ/GNA11 Q209L/P mutations, suggesting that these aberrant G-protein oncogenes mediate, at least in part, their effect through this hallmark proliferation pathway. 82, 83 Additional work showed that small molecule inhibition of PKC in GNAQ/11 mutant cells diminished cellular proliferation, 84 and the combined inhibition of PKC and MEK further enhanced the antitumor effect.
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Targeting the MEK-ERK pathway was given some support by early phase 1 and 2 clinical trials in metastasized UM in which single-agent small molecule MEK inhibitors (trametinib or selumetinib) showed a modest clinical benefit, 86,87 although not durable in nature. Importantly, preclinical experiments indicated that c-Jun-driven gene programs may be a mechanism by which constitutively active GNAQ/GNA11 mutant UM tumor cells circumvent therapeutic blockade of MEK inhibition. 82, 88 These observations were further bolstered by 2 studies that showed that mutant GNAQ/11 results in RhoA/Rac1-induced actin polymerization of G-actin to F-actin, triggering the dissociation of angiomotin, liberating YAP to translocate to the nucleus. 63, 89 These data indicated that although short-term GNAQ/GNA11 activation may be mediated through PLCβ-PKC and MEK-ERK pathways in UM, more chronic stimulation may also require the YAP pathway. A recent study provides important insight into the mechanism by which these multiple pathways may be regulated. Yoo et al 89 showed that mutant GNAQ forms a protein complex with the guanine nucleotide exchange factor GEF100, which activates the small GTPase ARF6. 90 This complex formation redistributes the aberrant, constitutively active GNAQ from the cell surface to cytoplasmic vesicles, serving as a node from which the multiple signaling pathways associated with mutant GNAQ/11 emanate. This observation provides yet another means by which the aberrant GNAQ/11 molecular signal is differentially transmitted.
Most studies have been performed in the setting of investigating the effects of an already established UM tumor cell. To study the different stages of UM development, zebrafish models for UM are being set up. A study in zebrafish, however, observed a lack of association between a mutation in GNAQ/11 and overall activation of the ERK1/2 pathway, indicating that these 2 genes may play a different role in early formation of benign tumors. Mouti et al 90 modified a zebrafish highly conserved GNAQ orthologue by substituting the conserved glutamine (Q) at position 209 with proline (P). 91 The vector used to modify the embryonic DNA also included a mitfa promoter fragment and a gene that would lead to expression of green fluorescent protein. This helped to detect fish carrying the mutation, as their lenses would show green fluorescence. The transgenic animals that carried the GNAQ mutation under the control of zebrafish mitfa promoter developed choroidal hyperplasia. Transgenic animals that carried mutations in NRAS Q61L or BRAF V600E did not show changes in choroidal melanocytes. YAP and ERK1/2 were only expressed at the interface of the retinal pigment epithelium and the choroid, where capillaries are concentrated, and not in the other parts of the choroidal hyperplasia and may therefore play a role in the stimulation of blood vessel growth. Interestingly, hyperactivation of the GNAQ proteins stimulated melanin synthesis in cutaneous melanocytes. When these investigators evaluated the association between GNAQ mutation and ERK in human cell lines derived from 3 distinct patients, they observed variable degrees of reduction in ERK phosphorylation upon knockdown of GNAQ as observed in earlier studies, further suggesting a context dependency.
Upregulation of the NF-kB pathway is common in a subpopulation of M3 tumors 92 and is partly due to the presence of tumorinfiltrating lymphocytes. It may be that an initial upregulation is related to the development of mutations in GNAQ/GNA11, which are supposed to bring about the activation of the MAPK pathway through PLC and PKC. 85 Protein kinase C inhibitor AEB071 inhibited ERK1/2 phosphorylation in GNAQ mutant UM cells, although it did not lead to reduced total ERK1/2 levels. In addition, AEB071 reduced nuclear p65 levels and reduced the DNA binding activity of NF-kB. Suppression of NF-kB led to growth inhibition of UM cells. 84 The link between the MAPK pathway and NF-kB may relate to the presence of inflammation in some UM, as NF-kB 
